277 related articles for article (PubMed ID: 33658690)
1. Hippo signalling maintains ER expression and ER
Ma S; Wu Z; Yang F; Zhang J; Johnson RL; Rosenfeld MG; Guan KL
Nature; 2021 Mar; 591(7848):E1-E10. PubMed ID: 33658690
[No Abstract] [Full Text] [Related]
2. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.
Britschgi A; Duss S; Kim S; Couto JP; Brinkhaus H; Koren S; De Silva D; Mertz KD; Kaup D; Varga Z; Voshol H; Vissieres A; Leroy C; Roloff T; Stadler MB; Scheel CH; Miraglia LJ; Orth AP; Bonamy GM; Reddy VA; Bentires-Alj M
Nature; 2017 Jan; 541(7638):541-545. PubMed ID: 28068668
[TBL] [Abstract][Full Text] [Related]
3. TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation.
Pefani DE; Pankova D; Abraham AG; Grawenda AM; Vlahov N; Scrace S; O' Neill E
Mol Cell; 2016 Jul; 63(1):156-66. PubMed ID: 27292796
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER
Ma S; Tang T; Probst G; Konradi A; Jin C; Li F; Gutkind JS; Fu XD; Guan KL
Nat Commun; 2022 Feb; 13(1):1061. PubMed ID: 35217640
[TBL] [Abstract][Full Text] [Related]
5. The molecular crosstalk of the hippo cascade in breast cancer: A potential central susceptibility.
Parambil ST; Antony GR; Littleflower AB; Subhadradevi L
Biochimie; 2024 Jul; 222():132-150. PubMed ID: 38494109
[TBL] [Abstract][Full Text] [Related]
6. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
7. RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2.
Roßwag S; Sleeman JP; Thaler S
Cells; 2021 Oct; 10(11):. PubMed ID: 34831091
[TBL] [Abstract][Full Text] [Related]
8. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
Li W; Cooper J; Zhou L; Yang C; Erdjument-Bromage H; Zagzag D; Snuderl M; Ladanyi M; Hanemann CO; Zhou P; Karajannis MA; Giancotti FG
Cancer Cell; 2014 Jul; 26(1):48-60. PubMed ID: 25026211
[TBL] [Abstract][Full Text] [Related]
9. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
[TBL] [Abstract][Full Text] [Related]
10. LATS2 condensates organize signalosomes for Hippo pathway signal transduction.
Qin M; Geng E; Wang J; Yu M; Dong T; Li S; Zhang X; Lin J; Shi M; Li J; Zhang H; Chen L; Cao X; Huang L; Wang M; Li Y; Yang XP; Zhao B; Sun S
Nat Chem Biol; 2024 Jun; 20(6):710-720. PubMed ID: 38200110
[TBL] [Abstract][Full Text] [Related]
11.
Tsoi M; Morin M; Rico C; Johnson RL; Paquet M; Gévry N; Boerboom D
FASEB J; 2019 Oct; 33(10):10819-10832. PubMed ID: 31268774
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase.
Ma B; Chen Y; Chen L; Cheng H; Mu C; Li J; Gao R; Zhou C; Cao L; Liu J; Zhu Y; Chen Q; Wu S
Nat Cell Biol; 2015 Jan; 17(1):95-103. PubMed ID: 25438054
[TBL] [Abstract][Full Text] [Related]
13. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
[TBL] [Abstract][Full Text] [Related]
14. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
[TBL] [Abstract][Full Text] [Related]
15. Wnt Signaling Promotes Breast Cancer by Blocking ITCH-Mediated Degradation of YAP/TAZ Transcriptional Coactivator WBP2.
Lim SK; Lu SY; Kang SA; Tan HJ; Li Z; Adrian Wee ZN; Guan JS; Reddy Chichili VP; Sivaraman J; Putti T; Thike AA; Tan PH; Sudol M; Virshup DM; Chan SW; Hong W; Lim YP
Cancer Res; 2016 Nov; 76(21):6278-6289. PubMed ID: 27578003
[TBL] [Abstract][Full Text] [Related]
16. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway.
Zhang J; Ji JY; Yu M; Overholtzer M; Smolen GA; Wang R; Brugge JS; Dyson NJ; Haber DA
Nat Cell Biol; 2009 Dec; 11(12):1444-50. PubMed ID: 19935651
[TBL] [Abstract][Full Text] [Related]
17. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling.
Zheng L; Xiang C; Li X; Guo Q; Gao L; Ni H; Xia Y; Xi T
J Hematol Oncol; 2018 May; 11(1):72. PubMed ID: 29848346
[TBL] [Abstract][Full Text] [Related]
18. The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway.
Salah Z; Itzhaki E; Aqeilan RI
Oncotarget; 2014 Nov; 5(21):10886-900. PubMed ID: 25350971
[TBL] [Abstract][Full Text] [Related]
19. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
[TBL] [Abstract][Full Text] [Related]
20. Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ.
Xekouki P; Lodge EJ; Matschke J; Santambrogio A; Apps JR; Sharif A; Jacques TS; Aylwin S; Prevot V; Li R; Flitsch J; Bornstein SR; Theodoropoulou M; Andoniadou CL
Endocr Relat Cancer; 2019 Jan; 26(1):215-225. PubMed ID: 30139767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
